Advances in Risk-Stratification and Therapeutic Options for Early-Stage Non–Small Cell Lung Cancer - Episode 1

Advances in Risk-Stratification and Therapeutic Options for Early-Stage Non–Small Cell Lung Cancer

This publication reviews the role of adjuvant therapy with targeted agents, particularly with third-generation epidermal growth factor receptor tyrosine kinase inhibitors, for the treatment of non–small-cell lung cancer, recapping key insights from a scientific interchange & workshop.

Now Viewing
EP. 1: Advances in Risk-Stratification and Therapeutic Options for Early-Stage Non–Small Cell Lung Cancer
EP. 2: Dr. Bordoni on the Utility of Adjuvant Osimertinib in ​EGFR-Mutant Lung Cancer
EP. 3: Dr. Lazar on Risk Stratification for Chemotherapy and Adjuvant Therapy in Lung Cancer
EP. 4: Dr. Langer on the Need for Reflex Testing in NSCLC

Related Content:

Advances in Risk-Stratification and Therapeutic Options for Early-Stage Non–Small Cell Lung Cancer
Dr. Langer on the Need for Reflex Testing in NSCLC
Dr. Lazar on Risk Stratification for Chemotherapy and Adjuvant Therapy in Lung Cancer
Dr. Bordoni on the Utility of Adjuvant Osimertinib in ​EGFR-Mutant Lung Cancer